Materials • Major Chemicals
$1.22 ▼ -0.04
(-3.17%)
MKT CAP: $133.6M • VOL: 917.3K
52W L $1 52W H $3
CDXS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $70.4M | $59.3M | $70.1M |
| YoY Revenue Growth % | +18.6% | -15.4% | — |
| Gross Profit | $61.0M | $43.1M | — |
| Gross Margin % | 86.7% | 72.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$41.7M | -$58.5M | -$68.1M |
| Operating Margin % | -59.3% | -80.0% | -80.0% |
| Net Income (GAAP) | -$44.0M | -$65.3M | -$76.2M |
| EBITDA (Normalized) | -$38.2M | -$55.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$19.4M | -$49.4M | -$52.6M |
| Capital Expenditures (CapEx) | $4.5M | $4.3M | — |
| Free Cash Flow (FCF) | -$23.8M | -$53.7M | -$52.6M |
| FCF Margin % | -33.9% | -80.0% | -75.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $50.8M | $19.3M | — |
| Total Debt (Short + Long Term) | $40.1M | $28.9M | — |
| Total Stockholders' Equity | $50.5M | $66.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CDXS.